Skip to main content
Clinical Trials/NCT05731284
NCT05731284
Active, not recruiting
Not Applicable

Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery

University of Alabama at Birmingham1 site in 1 country60 target enrollmentJuly 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pelvic Organ Prolapse
Sponsor
University of Alabama at Birmingham
Enrollment
60
Locations
1
Primary Endpoint
Anterior wall descensus measured by the POP-Q System, Ba point
Status
Active, not recruiting
Last Updated
10 months ago

Overview

Brief Summary

The purpose of the study is to evaluate the surgical outcomes of injecting platelet-rich plasma (PRP) into the vaginal tissue as an adjunct therapy at the time of prolapse surgery

Detailed Description

Platelet rich plasma (PRP) is an autologous product with high levels of platelets which are concentrated with bioactive growth factors responsible for accelerating tissue healing by stimulating the number of reparative cells to create collagen production, angiogenesis and neurogenesis. The overarching goal is to evaluate the effectiveness and safety of the adjunct application of PRP in the fibromuscular connective tissue (the site of anterior tissue plication) at the time of anterior colporrhaphy (the site of highest recurrence risk) in women undergoing native tissue vaginal prolapse repair, to promote tissue healing and regeneration, thus to improve surgical outcomes.

Registry
clinicaltrials.gov
Start Date
July 1, 2023
End Date
December 31, 2028
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Isuzu Meyer

Associate Professor

University of Alabama at Birmingham

Eligibility Criteria

Inclusion Criteria

  • Desire surgical treatment via a transvaginal native tissue approach.
  • Completed child-bearing

Exclusion Criteria

  • Unable to follow-up, not willing to, or unable to participate in the proposed study
  • Prior pelvic surgery within the past 12 months
  • Prior anterior/apical suspension procedures
  • Prior graft augmented prolapse surgery
  • Pelvic/abdominal radiation
  • Pelvic mass
  • History of solid organ malignancy

Outcomes

Primary Outcomes

Anterior wall descensus measured by the POP-Q System, Ba point

Time Frame: 12 month

Anterior wall descensus measured by the POP-Q System, Ba point

Secondary Outcomes

  • Apical wall descensus measured by the POP-Q System, C point(12 months)
  • Safety outcomes(12 months)
  • Retreatment(12 months)
  • Leading edge(12 months)
  • Posterior wall descensus(12 months)
  • Subjective(12 months)

Study Sites (1)

Loading locations...

Similar Trials